Modern treatment strategies in rheumatoid arthritis: Impact on, and predictors of, disease activity and disease course

Danish Medical Bulletin

Volumn 58, Issue 11, 2011, Pages

  Hetland, Merete Lund ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETAMETHASONE; C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADD ON THERAPY; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW; BONE MARROW EDEMA; BONE RADIOGRAPHY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENOTYPE; GROUPS BY AGE; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; JOINT SWELLING; LIVER DISEASE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MAINTENANCE DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; MUSCLE STIFFNESS; MYCOSIS; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHYSICAL DISABILITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYNOVITIS; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VISUAL ANALOG SCALE;

EID: 81155125629     PISSN: None     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (167)

1. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54(5):1401-9.
2. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying antirheumatic drugs in early rheumatoid arthritis: secondyear clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67(6):815-22.
3. Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, Jacobsen S et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69(10):1789-95.
4. Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68(3):384-90.
5. Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005; 34(1):40-4.
6. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008; 67(7):1023-6.
7. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62(1):22-32.
8. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93(4):551-6.
9. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27(8):864-72.
10. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43(1):8-17.
11. Kelley. Textbook of Rheumatology. 7th ed. 2005.
12. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important? J Rheumatol 2010; 37(2):285-90.
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6):727-35.
14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1):44-8.
15. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24(10):1308-15.
16. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7(4):R796-R806.
17. Thorsen H, Hansen TM, McKenna SP, Sorensen SF, Whalley D. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 2001; 30(2):103-9.
18. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14(6):706-20.
19. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18(4):481-91.
20. Sharp JT. Radiographic evaluation of the course of articular disease. Clin Rheum Dis 1983; 9(3):541-57.
21. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26(3):743-5.
22. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67 Suppl 3:iii2-25.
23. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. J Rheumatol 2005; 32(11):2250-6.
24. Schefte DB, Hetland ML. An open-source, selfexplanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology (Oxford) 2010; 49:99-104.
25. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312(13):818-22.
26. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350(9074):309-18.
27. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353(9164):1568-73.
28. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2002; 46(5):1164-70.
29. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5(10):531-41.
30. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333(3):137-41.
31. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 2003; 42(12):1545-9.
32. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G. Rheumatoid arthritis: a disease of Tlymphocyte/ macrophage immunoregulation. Lancet 1981; 2(8251):839-42.
33. Rodriguez F, Krayenbuhl JC, Harrison WB, Forre O, Dijkmans BA, Tugwell P et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum 1996; 39(9):1491-8.
34. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353(9149):259-66.
35. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333(3):142-6.
36. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al. Treatment of poorprognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43(8):1809-19.
37. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996; 124(8):773-4.
38. Wilske KR, Healey LA. Remodeling the pyramid--a concept whose time has come. J Rheumatol 1989; 16(5):565-7.
39. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the sawtooth strategy. J Rheumatol Suppl 1990; 22:12-5.
40. Schenkier S, Golbus J. Treatment of rheumatoid arthritis. New thoughts on the classic pyramid approach. Postgrad Med 1992; 91(1):285-92.
41. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54(12):944-7.
42. Jacobsen S, Garred P, Madsen HO, Heegaard NH, Hetland ML, Stengaard-Pedersen K et al. Mannosebinding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anticyclic citrullinated peptide-positive patients with early rheumatoid arthritis. J Rheumatol 2009; 36(4):731-5.
43. Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jorgensen A, Tarp U et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drugnaive compared with patients with osteoarthritis and controls. J Rheumatol 2009; 36(9):1885-91.
44. Christensen AF, Sorensen GL, Horslev-Petersen K, Holmskov U, Lindegaard HM, Junker K et al. Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis. Arthritis Res Ther 2010; 12(2):R39.
45. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61(9):793-8.
46. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47(1):17-21.
47. Sokka T, Krishnan E, Hakkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48(1):59-63.
48. Kvien TK, Uhlig T. The Oslo experience with arthritis registries. Clin Exp Rheumatol 2003; 21(5 Suppl 31):S118-S122.
49. van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003; 5(6):R347-R351.
50. Hetland ML. DANBIO--powerful research database and electronic patient record. Rheumatology (Oxford) 2011; 50(1):69-77.
51. van der Kooij SM, de Vries-Bouwstra JK, Goekoop- Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007; 66(10):1356-62.
52. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(7):1814-27.
53. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146(11):797-808.
54. Ostergaard M, Unkerskov J, Linde L, Krogh NS, Ravn T, Ringsdal VS et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheumatol 2007; 36(2):151-4.
55. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45(12):1558-65.
56. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47(4):495-9.
57. Norgaard F. Earliest roentgenological changes in polyarthritis of the rheumatoid type: Rheumatoid arthritis. Radiology 1965; 85:325-9.
58. de Carvalho A. Discriminative power of Larsen's grading system for assessing the course of rheumatoid arthritis. Acta Radiol Diagn (Stockh) 1981; 22:77-80.
59. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22):1586-93.
60. Ostergaard M, Ornbjerg LM, Boyesen P, Thormann A, Tarp U, Rogind H et al. TNF inhibitors reduce radiographic joint destruction by 65% in rheumatoid arthritis patients treated in clinical practice. Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 68[S3], 121-2. 2009.
61. Ornbjerg LM, Ostergaard M, Boyesen P, Thormann A, Tarp U, Rogind H et al. Predictors of radiographic joint destruction in rheumatoid arthritis patients during TNFinhibitor treatment in clinical practice. Arthritis and Rheumatism 60[10], S377. 2009.
62. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002; 47(2):215-8.
63. Vasiliauskiene L, Wiik A, Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60(5):459-66.
64. Kimura A, Sasazuki T. Eleventh International Histocompatibility workshop reference protocol for the HLA DNA typing technique. In: Tsuji K, Aizawa M, Sasazuki M, editors. HLA 1991. Oxford: Oxford University Press; 1992.
65. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30(6):1385-6.
66. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54(2):600-6.
67. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 1998; 17(19):2265-81.
68. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org. [Vienna, Austria: R Foundation for Statistical Computing; 2006.
69. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46(2):347-56.
70. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum 2004; 50(7):2072-81.
71. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004; 50(11):3432-43.
72. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54(1):26-37.
73. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, doubleblind, parallel treatment trial. Lancet 2008; 372(9636):375-82.
74. Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis 2003; 62(8):764-6.
75. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364(9430):263-9.
76. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van ZD, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52(11):3381-90.
77. Verstappen SM, Jacobs JW, van dVMJ, Heurkens AH, Schenk Y, ter Borg EJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66(11):1443-9.
78. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van ZD, Kerstens PJ, Hazes JM et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146(6):406-15.
79. Williams HJ, Willkens RF, Samuelson CO, Jr., Alarcon GS, Guttadauria M, Yarboro C et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28(7):721-30.
80. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46(2):328-46.
81. Fox RI, Morgan SL, Smith HT, Robbins BA, Choc MG, Baggott JE. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7- hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) 2003; 42(8):989-94.
82. Conaghan PG, O'Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003; 48(1):64-71.
83. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002; 29(10):2077-83.
84. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58(3):156-63.
85. Savnik A, Malmskov H, Thomsen HS, Graff LB, Nielsen H, Danneskiold-Samsoe B et al. MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions. Eur Radiol 2002; 12(5):1203-10.
86. Lindegaard HM, Vallo J, Horslev-Petersen K, Junker P, Ostergaard M. Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Ann Rheum Dis 2006; 65(9):1208-12.
87. Tanaka N, Sakahashi H, Ishii S, Sato E, Hirose K, Ishima T. Synovial membrane enhancement and bone erosion by magnetic resonance imaging for prediction of radiologic progression in patients with early rheumatoid arthritis. Rheumatol Int 2005; 25(2):103-7.
88. Palosaari K, Vuotila J, Takalo R, Jartti A, Niemela RK, Karjalainen A et al. Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study. Rheumatology (Oxford) 2006; 45(12):1542-8.
89. Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008; 67(6):794-800.
90. Ejbjerg BJ, Narvestad E, Jacobsen S, Thomsen HS, Ostergaard M. Optimised, low cost, low field dedicated extremity MRI is highly specific and sensitive for synovitis and bone erosions in rheumatoid arthritis wrist and finger joints: comparison with conventional high field MRI and radiography. Ann Rheum Dis 2005; 64(9):1280-7.
91. McQueen FM, Ostendorf B. What is MRI bone oedema in rheumatoid arthritis and why does it matter? Arthritis Res Ther 2006; 8(6):222.
92. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus AH, Kainberger F et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007; 56(4):1118-24.
93. Symmons DP. Environmental factors and the outcome of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17(5):717-27.
94. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63(9):1090-5.
95. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64(2):196-201.
96. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67(2):212-7.
97. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006; 65(4):453-8.
98. Mattey DL, Thomson W, Ollier WE, Batley M, Davies PG, Gough AK et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007; 56(5):1408-16.
99. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56(10):3236-47.
100. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(6):734-40.
101. Finckh A, Dehler S, Costenbader KH, Gabay C. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007; 66(8):1066-71.
102. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194):1932-9.
103. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4):253-9.
104. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343(22):1594-602.
105. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28(6):1238-44.
106. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1):35-45.
107. Klareskog L, van der HD, de Jager JP, Gough A, Kalden J, Malaise M et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410):675-81.
108. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33(12):2398-408.
109. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007; 46(7):1140-7.
110. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54(11):3399-407.
111. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007; 66(11):1473-8.
112. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007; 46:1153-6.
113. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007; 57(4):679-85.
114. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2:ii30-ii33.
115. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64(9):1274-9.
116. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2:ii13-ii16.
117. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148(2):124-34.
118. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Metaanalysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28(6):553-9.
119. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848.
120. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67(9):1229-34.
121. Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61(5):560-8.
122. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007; 74(2):148-54.
123. Furst DE. Observational cohort studies and well controlled clinical trials--we need them both! J Rheumatol 2004; 31(8):1476-7.
124. Young A, Huizinga T. Early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23(1):1-2.
125. Young A. What have we learnt from early rheumatoid arthritis cohorts? Best Pract Res Clin Rheumatol 2009; 23(1):3-12.
126. Kvien TK, Mikkelsen K, Nordvag BY. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol 2003; 30(6):1135-7.
127. Pincus T, Callahan LF. Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate more favourable outcomes than studies of patients with established disease. Br J Rheumatol 1995; 34(3):196-9.
128. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8):2122-7.
129. Askling J, Fored M, Baecklund E, Brandt L, Backlin C, Ekbom A et al. Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and characteristics following TNF- antagonists. Ann Rheum Dis 2005; 64:1414-20.
130. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56(9):2896-904.
131. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-8.
132. Scott DL. What have we learnt about the development and progression of early RA from RCTs? Best Pract Res Clin Rheumatol 2009; 23(1):13-24.
133. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18(9):1290-7.
134. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002; 46(2):283-5.
135. Finckh A, Liang MH, van Herckenrode CM, de PP. Longterm impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 2006; 55(6):864-72.
136. Willkens RF, Urowitz MB, Stablein DM, McKendry RJ, Jr., Berger RG, Box JH et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992; 35(8):849-56.
137. Ferraz MB, Pinheiro GR, Helfenstein M, Albuquerque E, Rezende C, Roimicher L et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand J Rheumatol 1994; 23(5):231-6.
138. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995; 38(12):1799-806.
139. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36(10):1082-8.
140. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58(4):220-5.
141. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005; 52(5):1360-70.
142. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66(2):235-41.
143. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9):726-33.
144. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914-21.
145. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann Rheum Dis 2009; 68(7):1105-12.
146. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374(9688):430-2.
147. Freeman-Narrod M, Gerstley BJ, Engstrom PF, Bornstein RS. Comparison of serum concentrations of methotrexate after various routes of administration. Cancer 1975; 36(5):1619-24.
148. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36(1):86-90.
149. Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis 2001; 60(4):432.
150. Burbage G, Gupta R, Lim K. Intramuscular methotrexate in inflammatory rheumatic disease. Ann Rheum Dis 2001; 60(12):1156.
151. Rozin A, Schapira D, Balbir-Gurman A, Braun-Moscovici Y, Markovits D, Militianu D et al. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002; 61(8):756-7.
152. Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) 2003; 42(8):1009-10.
153. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63(10):1232-4.
154. Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol 2006; 35(2):102-6.
155. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002; 136(1):76-8.
156. Svensson B, Boonen A, Albertsson K, van der HD, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a twoyear randomized trial. Arthritis Rheum 2005; 52(11):3360-70.
157. Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol 2005; 32(9):1691-8.
158. Jones A, Regan M, Ledingham J, Pattrick M, Manhire A, Doherty M. Importance of placement of intra-articular steroid injections. BMJ 1993; 307(6915):1329-30.
159. Luz KR, Furtado RN, Nunes CC, Rosenfeld A, Fernandes AR, Natour J. Ultrasound-guided intra-articular injections in the wrist in patients with rheumatoid arthritis: a double-blind, randomised controlled study. Ann Rheum Dis 2008; 67(8):1198-200.
160. Cunnington J, Marshall N, Hide G, Bracewell C, Isaacs J, Platt P et al. A randomised, controlled, double blinded study of ultrasound guided corticosteroid joint injection in patients with inflammatory arthritis. Arthritis Rheum 2010; 62(7):1862-9.
161. Horslev-Petersen K, Stengaard-Pedersen K, Tarp U, Svendsen A, Lauridsen UB, Lottenburger T et al. Intraarticular Glucocorticosteroid Therapy In Early Rheumatoid Arthritis. Influence Of Joint Localization And Number Of Previous Injections On The Duration Of Suppression Of Clinical Synovitis. Arthritis and Rheumatism 52[9], S1504. 2005. Ref Type: Abstract
162. Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a populationbased study. Arthritis Rheum 2006; 54(1):54-9.
163. Pavelka K, Gatterova J, Tegzova D, Jarosova K, Tomasova SJ, Svobodnik A et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Clin Exp Rheumatol 2007; 25(4):540-5.
164. van der Kooij SM, le CS, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van ZD, Kerstens PJ et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009; 68:1153-8.
165. van Zeben D., Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol 1993; 20(8):1288-96.
166. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Rasmussen C, Jensen DV et al. What Factors Influence the Health Status of Patients with Rheumatoid Arthritis Measured by the SF-12v2Health Survey and the Health Assessment Questionnaire? J Rheumatol 2009; 36:2183-9.
167. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008; 14(9-10):575-81.